Australian and New Zealand origin FBS carries the strongest TSE/BSE documentation for EMA submissions — both countries are classified as OIE Negligible Risk with no indigenous BSE. EDQM CEP is available for both origins. EU-origin FBS is also accepted and can simplify import documentation for DACH-based manufacturers. US-origin FBS (USDA 9CFR) is preferred for FDA IND/BLA submissions.

SeamlessBio offers batch reservation for 12–36 months for ATMP, GMP manufacturing, and clinical vaccine production programmes — covering the full journey from process development through Phase I/II clinical batch production. This ensures the same lot specification throughout the campaign without risk of gap or lot change that would trigger process re-validation.

Gamma irradiation (≥25 kGy) is not universally mandated but is increasingly specified for GMP viral vaccine production in BSL-2/3 facilities to provide an additional assurance of viral safety beyond standard adventitious agent testing. SeamlessBio provides gamma-irradiated FBS with full dose mapping certificate and validation documentation per ISO 11137. This is also specified in some WHO and ICH Q5A-aligned FBS procurement guidelines.

Standard FBS contains tetracycline residues at 10–100 ng/mL from routine antibiotic use in bovine husbandry. Tet-On and Tet-Off inducible promoter systems — used in AAV packaging cell lines, lentiviral vector production, and CAR-T construct systems — are suppressed by tetracycline at concentrations as low as 1–10 ng/mL. Standard FBS can partially or completely suppress inducible transgene expression, causing researchers to incorrectly conclude their construct is non-functional. FBS Tet-Free <10 ng/mL is mandatory for any Tet-regulated application.